Related Experiment Video

Updated: Oct 9, 2026

Formation of Covalent DNA Adducts by Enzymatically Activated Carcinogens and Drugs In Vitro and Their Determination by 32P-postlabeling
09:33

Formation of Covalent DNA Adducts by Enzymatically Activated Carcinogens and Drugs In Vitro and Their Determination by 32P-postlabeling

Published on: March 20, 2018

Human CYP1B1 and anticancer agent metabolism: mechanism for tumor-specific drug inactivation?

B Rochat1, J M Morsman, G I Murray

  • 1Department of Medicine and Therapeutics, University of Aberdeen, Aberdeen, Scotland, UK.

The Journal of Pharmacology and Experimental Therapeutics
|February 13, 2001
PubMed

Insights

Several anticancer drugs inhibit cytochrome P450 1B1 (CYP1B1), an enzyme often found in tumors. This interaction could lead to drug resistance and impact chemotherapy effectiveness.

Area of Science:

  • Biochemistry
  • Pharmacology
  • Oncology

Background:

  • Cytochrome P450 1B1 (CYP1B1) metabolizes procarcinogens and xenobiotics.
  • CYP1B1 is present in various tumors but not adjacent normal tissues or liver.
  • This suggests CYP1B1's potential role in selective anticancer agent biotransformation within tumor cells.

Purpose of the Study:

  • To investigate the interaction between CYP1B1 and commonly used anticancer drugs.
  • To determine if CYP1B1 activity is inhibited by these agents.
  • To explore the implications of this interaction on chemotherapy efficacy and drug resistance.

Main Methods:

  • An ethoxyresorufin deethylase assay was employed to screen interactions.
  • Kinetic parameters (K(i), K(m), V(max)) were determined for inhibitory and metabolic interactions.
  • In vitro incubations were performed to identify metabolites, such as 2-hydroxyflutamide.

Main Results:

  • Flutamide, paclitaxel, mitoxantrone, and docetaxel were identified as competitive inhibitors of CYP1B1.
  • Doxorubicin and daunomycin acted as mixed inhibitors, while tamoxifen was a noncompetitive inhibitor.
  • CYP1B1 was found to be a major enzyme in flutamide biotransformation in tumors, producing 2-hydroxyflutamide.

Conclusions:

  • Several anticancer agents can inhibit CYP1B1 activity.
  • Drug inactivation by CYP1B1 may represent a novel mechanism of chemotherapy resistance.
  • Understanding these interactions is crucial for predicting clinical outcomes and optimizing treatment strategies.

More Related Videos

Evaluating the Effectiveness of Cancer Drug Sensitization In Vitro and In Vivo09:19

Evaluating the Effectiveness of Cancer Drug Sensitization In Vitro and In Vivo

Published on: February 6, 2015

Enhancement of Apoptotic and Autophagic Induction by a Novel Synthetic C-1 Analogue of 7-deoxypancratistatin in Human Breast Adenocarcinoma and Neuroblastoma Cells with Tamoxifen19:44

Enhancement of Apoptotic and Autophagic Induction by a Novel Synthetic C-1 Analogue of 7-deoxypancratistatin in Human Breast Adenocarcinoma and Neuroblastoma Cells with Tamoxifen

Published on: May 30, 2012

Related Concept Videos

Pharmacogenetics of Phase I Enzymes: Cytochrome P450 Isozymes01:28

Pharmacogenetics of Phase I Enzymes: Cytochrome P450 Isozymes

Cytochrome P450 (CYP450) enzymes are a superfamily of heme-containing monooxygenases that play a pivotal role in Phase I drug metabolism by catalyzing oxidation and reduction reactions.These enzymes transform lipophilic xenobiotics into more hydrophilic metabolites, facilitating subsequent Phase II conjugation and eventual excretion. The CYP450 family is classified into families (e.g., CYP1–CYP3) and subfamilies (e.g., CYP2A, CYP2C), based on amino acid sequence homology.CYP450 isoenzymes,...
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
Pharmacogenetics of Phase II Enzymes: N-acetyltransferase, Thiopurine S-methyltransferase, UDP-glucuronosyltransferase01:27

Pharmacogenetics of Phase II Enzymes: N-acetyltransferase, Thiopurine S-methyltransferase, UDP-glucuronosyltransferase

Phase II biotransformation reactions are essential for detoxifying and eliminating xenobiotics, including many pharmaceutical compounds. These reactions typically involve conjugation, the covalent attachment of polar endogenous groups such as glucuronic acid, sulfate, methyl, or acetyl moieties to functional groups introduced during Phase I metabolism. The resulting conjugates are more water-soluble, enabling efficient renal or biliary excretion.The major classes of Phase II enzymes include...
Pharmacogenetics of Drug Metabolism: Overview01:27

Pharmacogenetics of Drug Metabolism: Overview

Genetic polymorphism in drug metabolism is crucial to the inter-individual variability observed in drug responses. Drug metabolism primarily involves the chemical modification of drugs and other xenobiotics to enhance their elimination by increasing their polarity. Two main classes of enzymes mediate this biotransformation process: Phase I enzymes, primarily cytochrome P450s, catalyze oxidation and reduction reactions, while other enzymes, such as esterases, mediate hydrolysis, and Phase II...